Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
Part of Heart & circulation clinical trials.
The aim of this clinical trial is to explore the optimal preventative treatment strategy for non-flow-limiting vulnerable plaques. The main question it aims to answer is: Can interventional therapy further improve the outcome of non-flow-limiting vulnerable plaques on top of optimal pharmacologic therapy? Researchers will randomly assign patients who meet the inclusion criteria to preventative intervention plus optimal drug therapy (experimental group) or optimal drug therapy alone (control group). Participants will: Assigned to the control group: optimized drug therapy consisting of lifestyle improvement and intensive drug therapy including high-dose statin or other therapy to achieve target levels (low-density lipoprotein cholesterol \<1.4 mmol/L and decreased by 50% compared to the baseline). Lifestyle improvement and risk factor management included smoking cessation, nutritional optimization, physical activity, compliance with prescribed medications, and control of diabetes and hypertension. Assigned to the experimental group: all non-flow-limiting vulnerable plaques were treated with conventional second-generation drug-eluting stents. After the procedure, participants received dual antiplatelet therapy for about 12 months as well as other medications in the control group.
Summary from the official registry record.
Who can take part
- Successful completion of angiography, QFR or VFR, and OCT examinations
- Successful treatment of all culprit lesions and flow-limited lesions (QFR or VFR≤ 0.8)
- Reference vessel diameter between 2.5-4.0 mm on imaging assessment
- Lesion length ≤40 mm
- At least one significant stenosis (diameter reduction \>50%) demonstrated by angiography, with QFR or VFR \>0.80 and OCT-defined TCFA (fibrous cap thickness \<65μm, lipid arc \>90°)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if using advanced imaging (like OCT or IVUS) to guide placement of a newer type of stent (bioresorbable scaffold) can reduce future stent problems. It is for people with stable coronary artery disease who need a stent in a main heart artery.
This trial compares two ways doctors place heart stents in patients having a heart attack or unstable chest pain. One method uses ultrasound imaging inside the artery (IVUS), and the other uses standard X-ray imaging. The goal is to see which approach leads to better outcomes.
This study looks at whether information from heart scans taken during stent placement can help predict future heart problems. If you've already had a stent placed under OCT guidance, participating could help improve care for others.
This study compares how best to place a coronary stent (a small tube to keep an artery open) using modern techniques. It may help improve how safely and effectively stents are delivered in people with certain types of narrowed heart arteries.
This trial studies whether a specific stent (with no polymer coating) plus a single blood thinner plan with aspirin and another P2Y12 medicine is as safe and effective as the standard two-medicine plan after a STEMI heart attack. It may help people avoid longer exposure to stronger blood-thinning if the new approach works as well.
This trial is testing a way to shorten the time you need to take blood thinners after getting a specific type of heart stent. It uses a special camera (OCT) inside the artery to help decide if stents are placed well enough to allow less time on dual antiplatelet therapy.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.